Protection of Alzheimer’s disease progression by a human-origin probiotics cocktail
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Jan. 10, 2025
Microbiome
abnormalities
(dysbiosis)
significantly
contribute
to
the
progression
of
Alzheimer's
disease
(AD).
However,
therapeutic
efficacy
microbiome
modulators
in
protecting
against
these
ailments
remains
poorly
studied.
Herein,
we
tested
a
cocktail
unique
probiotics,
including
5
Lactobacillus
and
Enterococcus
strains
isolated
from
infant
gut
with
proven
modulating
capabilities.
We
aimed
determine
probiotics
cocktail's
ameliorating
AD
pathology
humanized
mouse
model
APP/PS1
strains.
Remarkably,
feeding
mice
1
×
1011
CFU
per
day
drinking
water
for
16
weeks
reduced
cognitive
decline
(measured
by
Morris
Water
Maze
test)
markers,
such
as
Aβ
aggregation,
microglia
activation,
neuroinflammation,
preserved
blood-brain
barrier
(BBB)
tight
junctions.
The
beneficial
effects
were
linked
inflammatory
microbiome,
leading
decreased
permeability
inflammation
both
systemic
circulation
brain.
Although
male
female
showed
overall
improvements
cognition
biological
females
did
not
exhibit
specific
markers
related
permeability,
suggesting
that
underlying
mechanisms
may
differ
depending
on
sex.
In
conclusion,
our
results
suggest
this
could
serve
prophylactic
agent
reduce
pathology.
This
is
achieved
beneficially
improving
intestinal
junction
proteins,
reducing
BBB,
decreasing
gut,
blood
circulation,
brain,
ultimately
mitigating
decline.
Language: Английский
Engineered nanoparticles for the treatment of Alzheimer’s disease
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 3, 2025
Alzheimer’s
disease
(AD)
is
one
of
the
most
common
diseases
characterized
by
neurodegeneration
and
becoming
a
major
public
health
problem
worldwide.
AD
manifested
mainly
progressive
impairments
in
cognition,
emotion,
language
memory
elderly
population.
Many
treatment
strategies
have
been
explored
for
decades;
however,
there
still
no
effective
way
to
address
root
cause
pathogenesis,
only
target
symptoms
improve
patient
cognitive
outcomes.
Intracerebral
administration
difficult
because
challenges
posed
blood‒brain
barrier
(BBB).
NPs
are
materials
with
sizes
between
1
100
nm
that
can
biocompatibility,
extend
half-life,
transport
macromolecules,
be
delivered
across
BBB
central
nervous
system,
exhibit
good
targeting
capabilities.
provide
new
ideas
terms
their
antiaging,
antineuroinflammatory,
antioxidative,
nerve
repair-promoting
effects.
In
this
manuscript,
we
first
describe
relationship
BBB.
Second,
introduce
application
nanoparticles
treatment.
Finally,
summarize
faced
AD.
Language: Английский